CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice

被引：1

作者：

Liu, Jiandong ^{[1
]}

Cang, Tianle ^{[1
]}

Jiang, Congli ^{[2
]}

Li, Kelei ^{[1
]}

Liu, Siyuan ^{[1
]}

Wang, Haixin ^{[1
]}

Wang, Meirong ^{[1
]}

Chen, Yan ^{[3
]}

Shao, Yan ^{[3
]}

Liu, Jiankai ^{[1
]}

机构：

[1] Beijing Minhai Biotechnol Co Ltd, Beijing 102600, Peoples R China

[2] Shenzhen Kangtai Biol Prod Co Ltd, Shenzhen 518000, Peoples R China

[3] Jiangsu Taipuriu Biotechnol Co Ltd, Taizhou Pharmaceut City 225300, Jiangsu, Peoples R China

来源：

FUTURE VIROLOGY | 2023年 / 18卷 / 07期

关键词：

CpG; neutralizing antibody; SARS-COV-2; vaccine; variants; TH1/TH2; BALANCE; B-CELLS; DNA; EFFICACY; SAFETY; MATURE;

D O I：

10.2217/fvl-2022-0172

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Aim: This study used CpG 684 as adjuvant of inactivated COVID-19 vaccine to detect a humoral and cellular immune response in mice. Materials & methods: We used 10 and 20 mu g CpG 684 as adjuvants of am inactivated COVID-19 vaccine to immunize mice. IgG, IgG1, IgG2a, IgG2b and IgM binding antibodies were detected in serum by ELISA. The IFN-gamma cytokine was detected by ELISPOT. Results: CpG 684 improved spike-specific IgG and IgM subtype binding antibodies and increased the neutralizing antibody titer against prototype, Delta and Beta strains. CpG 684 also improved cellular immune response. Conclusion: CpG 684 is an effective adjuvant for inactivated COVID-19 vaccine.

引用

页码：403 / 410

页数：8

共 34 条

[1] Emergence of Novel SARS-CoV-2 variants in India: second wave [J].

Adiga, Rama ;

Nayak, Varun .

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (11) :1578-+

[2] Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 [J].

Azkur, Ahmet Kursat ;

Akdis, Mubeccel ;

Azkur, Dilek ;

Sokolowska, Milena ;

van de Veen, Willem ;

Bruggen, Marie-Charlotte ;

O'Mahony, Liam ;

Gao, Yadong ;

Nadeau, Kari ;

Akdis, Cezmi A. .

ALLERGY, 2020, 75 (07) :1564-1581

[3] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[4] Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies [J].

Bian, Lianlian ;

Gao, Fan ;

Zhang, Jialu ;

He, Qian ;

Mao, Qunying ;

Xu, Miao ;

Liang, Zhenglun .

EXPERT REVIEW OF VACCINES, 2021, 20 (04) :365-373

[5]

Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]

[6]

Davis HL, 1998, J IMMUNOL, V160, P870

[7] Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine [J].

Falsey, Ann R. ;

Sobieszczyk, Magdalena E. ;

Hirsch, Ian ;

Sproule, Stephanie ;

Robb, Merlin L. ;

Corey, Lawrence ;

Neuzil, Kathleen M. ;

Hahn, William ;

Hunt, Julie ;

Mulligan, Mark J. ;

McEvoy, Charlene ;

DeJesus, Edwin ;

Hassman, Michael ;

Little, Susan J. ;

Pahud, Barbara A. ;

Durbin, Anna ;

Pickrell, Paul ;

Daar, Eric S. ;

Bush, Larry ;

Solis, Joel ;

Carr, Quito Osuna ;

Oyedele, Temitope ;

Buchbinder, Susan ;

Cowden, Jessica ;

Vargas, Sergio L. ;

Benavides, Alfredo Guerreros ;

Call, Robert ;

Keefer, Michael C. ;

Kirkpatrick, Beth D. ;

Pullman, John ;

Tong, Tina ;

Isaacs, Margaret Brewinski ;

Benkeser, David ;

Janes, Holly E. ;

Nason, Martha C. ;

Green, Justin A. ;

Kelly, Elizabeth J. ;

Maaske, Jill ;

Mueller, Nancy ;

Shoemaker, Kathryn ;

Takas, Therese ;

Marshall, Richard P. ;

Pangalos, Menelas N. ;

Villafana, Tonya ;

Gonzalez-Lopez, Antonio .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (25) :2348-2360

[8]

FDA, VACC BLOOD BIOL VACC

[9]

Gursel M, 2002, EUR J IMMUNOL, V32, P2617, DOI 10.1002/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO

[10]

2-F

← 1 2 3 4 →